Press Release


Biotics Research Launches Gluten-Free Awareness Campaign
Press Release
Written by Debra Fish   
Friday, 21 February 2014 13:44
Rosenberg, TX – February 20th, 2014 – Biotics Research Corporation, the industry leader in the development of superior, gluten-free nutritional supplements, has launched a full campaign to bring awareness to both healthcare providers and patients on the importance of gluten-free nutritional supplements.

“With such a large percentage of the population sensitive to gluten on some level, it’s imperative that patients take supplements that are free of gluten,” explained Denis DeLuca, President of Biotics Research. “We understand the challenges those with a gluten sensitivity face when trying to maintain a gluten-free diet, which is why we’ve taken great care to ensure that all of our products are gluten-free.”

Research shows that as many as 10 percent of the U.S. population has some level of gluten sensitivity. Gluten is problematic for those with gluten sensitivity because it inhibits the body’s ability to absorb nutrients and defend against would-be pathogens. The detrimental impact of gluten on the body for those with gluten sensitivity results in a variety of symptoms, including bloating, abdominal discomfort, pain, diarrhea, headaches and migraines, lethargy, attention-deficit disorder, muscular disturbances, bone and joint pain, among others. Given that gluten is ubiquitous in the standard American diet, eliminating it can be a challenge.

People with gluten sensitivity often fail to consider whether their supplements contain gluten. Biotics Research has taken the guesswork for both providers and patients from having to choose the right supplements as its entire catalog of almost 300 products are gluten free – and they always have been!

Biotics Research is creating print and online marketing and educational materials in its efforts to bring awareness to both practitioners and patients.

“More and more people are learning that many of the symptoms they’ve been having for years are a result of some level of gluten sensitivity,” added Denis. “And we understand that eliminating gluten from a diet can be a difficult challenge. Our gluten-free supplements are the perfect solution because those with gluten sensitivity no longer have to worry about whether the supplements they’re taking to try to improve and support their health could in fact be hindering it.”

To learn more about Biotics Research Corporation and its gluten-free catalog of supplements, please visit www.BioticsResearch.com or download the Biotics Research Mobile App at the Apple® App Store or Google® Play Store.

About Biotics Research Corporation
Biotics Research Corporation has been a leading manufacturer of specially designed, gluten-free nutritional supplements for nearly forty years. Our mission remains constant: to be the benchmark of excellence in nutritional science, technology and service, providing the clinician and their patients with reliable, innovative products of superior quality. Visit www.BioticsResearch.com.
####
 
Douglas Laboratories® Launches New Star Product, Sereniten Plus™
Press Release
Written by TAC Staff   
Thursday, 13 February 2014 15:23
Stress management and cortisol regulation support formula now available throughout North America

PITTSBURGH, Pa., February 11, 2014Douglas Laboratories®, the trusted choice of healthcare professionals for superior quality, science-based nutritional supplements for more than 50 years, is proud to announce the addition of Sereniten Plus™, to its existing line of products available in the United States. Developed by Penny Kendall-Reed, N.D., a specialist in metabolic disorders who is also a member of the Douglas Laboratories® Clinical Advisory Board, Sereniten Plus™ rapidly became a popular stress management support choice for Canadian healthcare practitioners.

sereniten-plus“Douglas Laboratories Canada has had great success partnering with Dr. Kendall-Reed to educate and promote Sereniten Plus in 2012 and 2013. This product, now available throughout North America, is the most successful new product launch to date,” said Andrew Halpner Ph.D., Vice President, Product Development and Technical Services at Douglas Laboratories.

“Sereniten Plus was developed to promote an anxiolytic effect - supporting mental and physical stress,”† said Dr. Kendall-Reed. “Lactium® is the only supplemental ingredient I have found to lower glucocorticoid secretion and rebalance the Hypothalamic-Pituitary-Adrenal pathway.”†

The Sereniten Plus™ formula consists of a combination of Lactium®, L-Theanine and Vitamin D to support the HPA axis and feedback loop for stress management and cortisol regulation. Lactium®, a bioactive decapeptide, and L-Theanine have been shown to provide a calming effect without drowsiness and support normal sleep that is affected by stress.† It is also unique in how it increases the sensitivity of the hypothalamus to cortisol, thereby re-establishing the receptor sensitivity and feedback within the HPA axis.

Results from studies have shown that 30 days of supplementation with Lactium® can result in lowered plasma cortisol levels and a reduction in stress related issues promoting digestion, cardiovascular, intellectual, emotional, and social wellbeing. †

Douglas Laboratories will host an educational webinar for healthcare professionals, presented by Penny Kendall-Reed, N.D., on February 12, 2014,and titled “Why Diets Fail - A Neuroendocrine Approach to Weight Loss.” To register for the webinar, or for further information on the Douglas Laboratories® Sereniten Plus™ formula, please visit douglaslabs.com.

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease.

ABOUT DOUGLAS LABORATORIES®
A business unit of Atrium Innovations Inc. (TSX: ATB & ATB.DB), Douglas Laboratories®, the trusted choice of thousands of healthcare professionals for over 50 years, is proudly researching, developing and manufacturing superior quality, science-based supplements that help people improve their health. Douglas Laboratories provides added insurance of multiple domestic and international GMP certifications, including ISO-9001 Certification and ISO-17025 accreditation for in-house laboratories, as well as NSF International Registration. With its headquarters located in Pittsburgh, Pennsylvania, USA, Douglas Laboratories currently offers over 600 branded products distributed worldwide. For additional information, please visit www.douglaslabs.com.

ABOUT DR. PENNY KENDALL-REED
Penny Kendall-Reed is a Naturopathic Doctor in Toronto.  After graduating from McGill University with a B.Sc. in Neurobiology, she attended the Canadian College of Naturopathic Medicine, where she earned her degree in Naturopathic Medicine and received the Dr. Allen Tyler Award for Most Outstanding Clinician.  As a specialist in metabolic disorders and author of a national best sellers, The Naturopathic Diet, and The New Naturopathic Diet, and co-author, The No Crave Diet, Healing Arthritis, The Complete Doctor’s Healthy Back Bible and The Complete Doctor’s Stress Solution Penny Kendall-Reed lectures throughout Canada and the United States.  She holds health retreats and lectures at various resorts worldwide, and appears regularly on television, magazine and radio across Canada and the United States addressing various health issues.  Penny Kendall-Reed has also designed an all natural oral and topical anti-aging skin care line called Age Aware Skin Care sold throughout the UK.  Presently, Penny Kendall-Reed is the director of natural therapies at the Urban Wellness Clinic in Toronto.

ABOUT ATRIUM INNOVATIONS
Atrium Innovations Inc. (TSX: ATB & ATB.DB) is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products which are distributed in more than 35 countries.  The Company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education.  Atrium has over 1,300 employees and operates seven manufacturing facilities complying with current Good Manufacturing Practices. Additional information is available at www.atrium-innovations.com.
 
Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments
Press Release
Written by TAC Staff   
Thursday, 13 February 2014 11:04
Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Brain, Bladder and Prostate Cancers

Toronto, Ontario – February 13, 2014 - Theralase Technologies Inc. (TSXV: TLT) reported today that a recently published scientific paper demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25). 

“The ability for the PDC technology to be effective in low oxygen environments is considered to be an essential factor in the recurrence and progression of non-muscle invasive bladder cancer. This form of disease represents up to 75% of newly diagnosed bladder cancer cases accounting for more than 386,000 cases and 150,000 deaths annually worldwide,” said Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. Dr. Mandel continued: “The abnormal decrease or the lack of oxygen supply to cells and tissues is called hypoxia and commonly presents in solid cancers, such as brain, bladder, breast, lung and prostate. Hypoxic cancers are extremely aggressive, resistant to standard therapies (chemotherapy and radiotherapy), and thus very difficult to destroy. Tumor hypoxia is known to play a role in cancer metastasis (spread) and resistance to therapy, as well as the ability of cancer cells to escape destruction by the immune system. The evidence supporting the Theralase PDC technology represents a potential solution for hypoxic cancers. In our work, we described a family of Theralase PDCs that have shown an ability to switch their photoreactivity from a Type II reaction (oxygen dependent) to a Type I (free radical mediated) reaction. This is strategic to the Company in that a Type I reaction is unique and opens the opportunity of using the PDCs beyond sterilization and the treatment of superficial cancerous lesions to the treatment of harder to treat tumours”.

Dr. Lothar Lilge, Senior Scientist  at the Princess Margaret Cancer Centre, University Health Network stated that, “In well oxygenated environments, these new PDCs generate singlet oxygen, a dominant cytotoxic substance with close to 100% efficacy, yet under hypoxia (low oxygen) conditions, they display the remarkable ability to switch to a Type I or oxygen independent cytotoxic substance owing to their ability to simultaneously act as an excited state oxidant and reductant. The intrinsic positive charge of the Ru(II) metal combined with the oxygen independent light activated cytotoxicity demonstrated by this family of PDCs opens a new strategy for destroying both gram-positive and gram-negative bacteria regardless of oxygenation level.  Therefore, this has a significant impact on the destruction of cancer cells by PDC technology, as a considerable fraction of cancer will survive in low oxygen environments and according to the literature this is one of the causes for recurrence of cancer post therapy.” 

Dr. Michael Jewett, Clinical Principal Scientific Investigator at Princess Margaret Cancer Centre, University Health Network and University of Toronto stated that, “I am extremely encouraged by the results of this scientific work and the implications that it may have in the destruction of bladder Transitional Cell Carcinoma, as the bladder is traditionally known as a very low oxygen environment. There has not been a new drug approved for bladder cancer since 1998 and I am looking forward to working with the Theralase team to initiate a Phase 1 / 2 clinical trial in 1Q2015.”

About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in healing injured tissue and destroying cancer.  Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint injuries. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated. 

Additional information is available at www.theralase.com and www.sedar.com 
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:
Roger Dumoulin-White,  
President & CEO
416-699-LASE (5273) ext. 225
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 
Essential Formula’s Line of Chia Omega Formulations Receives Respected NSF Certified for Sport® Product Certification
Press Release
Written by TAC Staff   
Friday, 07 February 2014 15:11
DALLAS, January 29, 2014 - Essential Formulas Incorporated’s line of award-winning CHIA OMEGA® formulations recently earned the NSF Certified for Sport® designation  (http://www.nsfsport.com/) from NSF International, one of the most respected independent product testing and certification organizations.

Scientists at NSF International tested Essential Formulas’ CHIA OMEGA products (www.chiaomega.com) to verify that these products comply with strict standards of NSF/ANSI 173, the only American national standard for dietary supplements which was developed through a consensus process involving input from regulatory, industry, sports and consumer groups.  This included testing to verify label accuracy and that the product did not contain any harmful levels of contaminants.

chia-omegaAdditionally, to earn NSF Certified for Sport® certification, CHIA OMEGA products were screened for more than 180 banned substances such as narcotics, steroids, stimulants, hormones and other related substances along with diuretics and other masking agents.  Essential Formulas’ manufacturing facility also was inspected to verify compliance with NSF’s current Good Manufacturing Practices (cGMP) facility registration program.

“This distinguished certification helps athletes as well as general consumers make more educated decisions when choosing dietary supplements,” said Michael Schoor, President and CEO of Essential Formulas.  “Our company was founded on the principles of transparency, education and product integrity and we are proud to earn the highly respected NSF Certified for Sport® designation for our CHIA OMEGA products.”

“Many professional athletes and sports organizations rely on NSF International’s Certified for Sport® program because it is the most rigorous testing and certification program available for sports nutrition and dietary supplement products,” said Lisa Thomas, General Manager of NSF’s Dietary Supplement programs.  “Essential Formulas’ participation in the program demonstrates their leadership and commitment in developing products of high quality and safety.”

The National Football League (NFL), Major League Baseball (MLB), National Hockey League (NHL), the Ladies Professional Golf Association (LPGA), PGA and the Canadian Centre for Ethics in Sport (CCES) utilize the NSF Certified for Sport® program to protect athletes from prohibited substances.

Athletes and consumers can find Essential Formulas’ NSF certified products on NSF International’s listings or by downloading the NSF Sport app.


About NSF International (www.nsf.org): Based in Ann Arbor, Mich., USA, NSF International is a global independent public health organization that writes standards, and tests and certifies products for the food, water, health sciences and consumer goods industries.  Established in 1944, NSF is committed to protecting human health and safety worldwide and operates in more than 150 countries.  NSF International has been collaborating with the World Health Organization since 1997 in water quality and safety, food safety and indoor environments.

The NSF Health Sciences Division offers training and education, consulting, auditing, GMP and GLP testing, GMP facility registration, product certification, R&D and regulatory guidance for the pharmaceutical, medical device and dietary supplement industries throughout the product lifecycle.  The division also supplies pharmaceutical secondary reference standards, traceable to USP and EP standards. NSF wrote the only accredited American National Standard (NSF/ANSI 173) that verifies the health and safety of dietary supplements and also tests and certifies products to this standard. The NSF Health Sciences Division operates globally throughout North America, Europe, the Middle East, Africa, Asia and Latin America.

About Essential Formulas (www.essentialformulas.com) Dallas-based Essential Formulas Incorporated (EFI) was established in 2000 as the sole U.S. distributor of world-renowned microbiologist Dr. Iichiroh Ohhira’s award-winning probiotic dietary supplements.  A family-owned and operated business, EFI was founded on the philosophy of providing high-quality preventative, supportive and comprehensive pro-health products for the entire family.  Pledging to provide premium all natural supplements and exceptional customer care, EFI continually strives to lead the industry in customer and retailer education in the use and efficacy of their innovative products, which include Dr. Ohhira’s Probiotics®formulations and the newly introduced CHIA OMEGA line of Omega-3 formulations.  Both Dr. Ohhira’s Probiotic formulations and CHIA OMEGA dietary supplements are available at Vitamin Shoppe, Whole Foods Markets and other fine health food stores across the country.  For more information, visit: www.essentialformulas.com, or call 972.255.3918.
 
Significantly Reduce Lower Back Pain without Surgery or Drugs
Press Release
Written by TAC Staff   
Thursday, 06 February 2014 14:54
fitnesstherapeutics240Portland, OR –Fitness Therapeutics Inc announces release of their new product Back in Action 1, a program designed to reduce lower back pain. It was developed for people with chronic pain or those who experience repeated acute injury to their back. The program, created by Dr. Bruce Farmer MD, is based on Trizone Movement Therapy™, a whole-body approach to personal health. The movements have been scientifically proven to reduce pain, restore fitness, and increase mobility by participants.

Fitness Therapeutics is a local company focused on home-based, whole body movement routines that are designed to restore balance, increase symmetry in the body and significantly reduce pain. The company offers several programs to relieve lower back pain, designed to be used in the comfort of one’s own home. They also offer fitness therapy, movement and walking classes at their Portland based headquarters.

Back in Action 1 is available at Fitnesstherapeutics.com/gettingstarted
trizone
 
«StartPrev12345678910NextEnd»

Page 4 of 24
 

requestmagazinebutton


Advertisement

Recent Comments


Advertisement

 

TAC Publications

The American Chiropractor Magazine: Digital Issues | Past Issues | Buyer's Guide

 

More Information

TAC Editorial: About | Circulation | Contact

Sales: Advertising | Subscriptions | Media Kit